Institutional 13F · Context Only · Never a Buy List机构 13F · 仅供背景参考 · 非买入清单
Casdin Capital
sector_healthcare
A
leaderboard rank榜单排名 #4
Book持仓规模
$1.3B
long US listed only仅美股多头
Positions持仓数
40
98% resolved已解析
Top-10 concentration前十集中度
77%
% of book占组合%
Turnover换手
LOW
17.8% per quarter每季
Median excess中位超额
+8%
buys vs SPY, since filing买入相对SPY，自申报起 · n 31
Hit rate胜率
64%
share of buys beating SPY跑赢SPY的买入占比
Core lean — the 10-second read核心倾向 — 10秒速读
Core lean: Genomics — added TXG, NTLA (+4.0pp of book this quarter)核心倾向：Genomics — 本季度加仓 TXG、NTLA（占组合 +4.0pp）
GenomicsGenomics
+4.0pp
11.2% of book held占组合持有
· 5 names标的
· Healthcare & Biotech
TXG
NTLA
DiagnosticsDiagnostics
+3.7pp
10.9% of book held占组合持有
· 4 names标的
· Healthcare & Biotech
TXG
GLP-1 & ObesityGLP-1 与减肥药
+2.4pp
6.7% of book held占组合持有
· 3 names标的
· Healthcare
SRRK
HIMS
Next-GenNext-Gen
+0.3pp
4.7% of book held占组合持有
· 3 names标的
· Healthcare & Biotech
NTLA
Health Care (Equal-Weight)医疗保健（等权）
+0.3pp
1.0% of book held占组合持有
· 2 names标的
· US Sectors (EW)
MRNA
Descriptive read of the latest filing — themes clustered from curated baskets (Finviz fallback), added-pp = Σ % of book bought this quarter. Not a forecast.基于最新申报的描述性解读——主题按精选篮子聚类（Finviz 兜底），added-pp = 本季度买入占组合百分比之和。非预测。
Grade & excess history评级与超额历史
per-quarter buy cohorts, scored on public filing dates vs SPY — descriptive ranks in a curated survivor cohort按季度买入队列，以公开申报日为锚相对SPY评分——精选幸存者队列中的描述性排名Reliability可靠性: · 9 scored quarters已评分季度 · 78% positive为正 · recent-4 median近4季中位 +25% vs all-time对全期 +30%
Median excess by quarter各季度中位超额: ▂█▇▃▁▃▂▃▃ (oldest → newest, shifted by the series minimum so negatives render由旧到新，按序列最小值平移以呈现负值)
| Quarter季度 | Buys买入数 | Median excess中位超额 | Hit胜率 | Median fwd 63d中位前瞻63日 |
|---|---|---|---|---|
| 2023-12-31 | 2 | -4% | 50% | -1% |
| 2024-06-30 | 2 | +204% | 100% | +1% |
| 2024-09-30 | 2 | +195% | 100% | +14% |
| 2024-12-31 | 2 | +30% | 50% | -68% |
| 2025-03-31 | 2 | -57% | 0% | -20% |
| 2025-06-30 | 3 | +55% | 67% | +43% |
| 2025-09-30 | 4 | +5% | 50% | -8% |
| 2025-12-31 | 8 | +18% | 75% | -8% |
| 2026-03-31 | 3 | +33% | 100% | — |
Sector exposure & rotation行业配置与轮动
value-weighted, latest filing; QoQ deltas vs prior quarter按市值加权，最新申报；季度环比变化对上季Current weights当前权重 · 2026-03-31
Unclassified
83.6%
▲ +2.6pp
Health Care
15.3%
▲ +0.0pp
Healthcare
1.0%
▼ -2.5pp
Theme categories主题类别
Healthcare 6.7%
US Sectors (EW) 1.0%
Artificial Intelligence 1.0%
Rotating into (QoQ)轮入（环比）
no QoQ increases无环比增持
Rotating out of (QoQ)轮出（环比）
Healthcare -2.5pp
Quarter history — top-3 sectors季度历史 — 前三大行业
| 2026-03-31 | Unclassified 84% · Health Care 15% · Healthcare 1% |
| 2025-12-31 | Unclassified 81% · Health Care 15% · Healthcare 4% |
| 2025-09-30 | Unclassified 78% · Health Care 20% · Healthcare 1% |
| 2025-06-30 | Unclassified 75% · Health Care 24% · Healthcare 1% |
| 2025-03-31 | Unclassified 73% · Health Care 26% · Healthcare 1% |
| 2024-12-31 | Unclassified 68% · Health Care 31% · Healthcare 1% |
| 2024-09-30 | Unclassified 68% · Health Care 32% · |
| 2024-06-30 | Unclassified 67% · Health Care 33% · |
| 2024-03-31 | Unclassified 74% · Health Care 26% · |
| 2023-12-31 | Unclassified 72% · Health Care 28% · |
| 2023-09-30 | Unclassified 74% · Health Care 26% · |
| 2023-06-30 | Unclassified 72% · Health Care 28% · Healthcare 0% |
Full book完整持仓
every resolved position as filed — click a column header to sort. Conviction is a descriptive composite, not a forecast.截至申报日的全部已解析持仓——点击列头排序。信念分为描述性综合指标，非预测。39 positions shown项持仓 · resolved已解析 39/40 (98%) · unresolved CUSIPs are excluded from this table but counted in book totals未解析CUSIP不列入本表，但计入组合总额
| #↕ | Ticker标的 ↕ | Company公司 ↕ | % book仓位% ↕ | Value金额 ↕ | Action动作 ↕ | Δ sharesΔ股数 ↕ | Add streak连加季数 ↕ | Conviction信念分 ↕ | Sector行业 ↕ | Themes主题 | Since filing自申报 ↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 |  RVMD |
Revolution Medicines Inc | 19.0% | $251M | hold | +0% | — | 70 · HIGH | — | — | — |
| 2 |  WGS |
Genedx Holdings Corp | 14.6% | $193M | hold | +0% | — | 69 · MODERATE | — | — | — |
| 3 |  RLAY |
Relay Therapeutics Inc | 10.9% | $143M | add | +11% | 2q | 78 · HIGH | — | — | — |
| 4 |  BLFS |
Biolife Solutions Inc | 8.6% | $114M | hold | +0% | — | 67 · MODERATE | Health Care | — | +38% |
| 5 |  LAB |
Standard Biotools Inc | 6.2% | $82M | hold | +0% | — | 66 · MODERATE | — | — | — |
| 6 |  ILMN |
Illumina Inc | 5.0% | $65M | trim | -12% | — | 66 · MODERATE | Health Care | Oncology, Diagnostics, Genomics | +32% |
| 7 |  GPCR |
Structure Therapeutics Inc | 4.3% | $57M | hold | +0% | — | 65 · MODERATE | — | GLP-1 & Obesity | +17% |
| 8 | TXG |
10x Genomics Inc | 3.7% | $48M | add | +62% | 2q | 74 · HIGH | — | Diagnostics, Genomics | — |
| 9 |  DNLI |
Denali Therapeutics Inc | 2.7% | $35M | hold | +0% | — | 63 · MODERATE | — | — | — |
| 10 |  BEAM |
Beam Therapeutics Inc | 2.4% | $32M | trim | -16% | — | 52 · MODERATE | — | Next-Gen | — |
| 11 |  GH |
Guardant Health Inc | 2.2% | $29M | trim | -17% | — | 36 · LOW | — | Oncology, Diagnostics, Genomics | +62% |
| 12 |  NGNE |
Neurogene Inc | 2.2% | $29M | hold | +10% | — | 35 · LOW | — | — | — |
| 13 |  ALNY |
Alnylam Pharmaceuticals Inc | 1.9% | $25M | hold | +0% | — | 34 · LOW | — | Next-Gen | — |
| 14 |  MAZE |
Maze Therapeutics Inc | 1.7% | $23M | hold | +0% | — | 33 · LOW | — | — | — |
| 15 | SRRK |
Scholar Rock Hldg Corp | 1.3% | $17M | add | +35% | 2q | 42 · LOW | — | GLP-1 & Obesity | +3% |
| 16 |  AGMB |
Agomab Therapeutics Nv | 1.2% | $16M | new | — | 1q | 26 · LOW | — | — | — |
| 17 | HIMS |
Hims & Hers Health Inc | 1.1% | $15M | add | +82% | 2q | 41 · LOW | Health Care | GLP-1 & Obesity | +33% |
| 18 |  TSHA |
Taysha Gene Therapies Inc | 1.1% | $15M | add | +117% | 2q | 41 · LOW | — | — | — |
| 19 |  TEM |
Tempus Ai Inc | 1.0% | $13M | hold | +0% | — | 29 · LOW | — | AI Agents & Applications | +20% |
| 20 |  SEPN |
Septerna Inc | 1.0% | $13M | hold | +0% | — | 29 · LOW | — | — | — |
| 21 |  GRAL |
Grail Inc | 0.9% | $12M | new | — | 1q | 32 · LOW | — | — | — |
| 22 |  PRME |
Prime Medicine Inc | 0.8% | $11M | hold | +0% | — | 26 · LOW | — | — | — |
| 23 |  PSNL |
Personalis Inc | 0.8% | $10M | new | — | 1q | 20 · LOW | — | — | — |
| 24 |  DGX |
Quest Diagnostics Inc | 0.7% | $10M | hold | +0% | — | 24 · LOW | Healthcare | Health Care (Equal-Weight) | +11% |
| 25 |  VCYT |
Veracyte Inc | 0.7% | $9M | hold | +0% | — | 24 · LOW | Health Care | — | +52% |
| 26 |  MLTX |
Moonlake Immunotherapeutics | 0.6% | $8M | new | — | 1q | 18 · LOW | — | — | — |
| 27 | NTLA |
Intellia Therapeutics Inc | 0.3% | $5M | new | — | 1q | 27 · LOW | — | Next-Gen, Genomics | — |
| 28 |  IRON |
Disc Medicine Inc | 0.3% | $4M | new | — | 1q | 16 · LOW | — | — | — |
| 29 | MRNA |
Moderna Inc | 0.3% | $4M | new | — | 1q | 25 · LOW | Healthcare | Health Care (Equal-Weight) | +37% |
| 30 |  ANL |
Adlai Nortye Ltd | 0.3% | $4M | new | — | 1q | 14 · LOW | — | — | — |
| 31 |  GLUE |
Monte Rosa Therapeutics Inc | 0.2% | $3M | add | +116% | 1q | 23 · LOW | — | — | — |
| 32 |  ABSI |
Absci Corporation | 0.2% | $3M | hold | +0% | — | 17 · LOW | — | — | — |
| 33 |  IPSC |
Century Therapeutics Inc | 0.2% | $3M | hold | +0% | — | 16 · LOW | — | — | — |
| 34 |  BBOT |
Bridgebio Oncology Therapeut | 0.2% | $3M | hold | +0% | — | 15 · LOW | — | — | — |
| 35 |  CTNM |
Contineum Therapeutics Inc | 0.1% | $2M | hold | +0% | — | 14 · LOW | — | — | — |
| 36 |  PACB |
Pacific Biosciences Calif In | 0.1% | $955372 | trim | -83% | — | 14 · LOW | — | Diagnostics, Genomics | — |
| 37 |  RXRX |
Recursion Pharmaceuticals In | 0.0% | $507542 | hold | +0% | — | 13 · LOW | — | Applications | — |
| 38 |  TNYA |
Tenaya Therapeutics Inc | 0.0% | $250627 | hold | +0% | — | 12 · LOW | — | — | — |
| 39 |  DNA |
Ginkgo Bioworks Holdings Inc | 0.0% | $223702 | hold | +0% | — | 12 · LOW | — | Alt Protein | — |
Rotation detail轮动明细
this filing cycle, uncapped — adds/new and trims from the resolved book, exits from the rotation feed本申报周期，不设上限——新建/加仓与减持取自已解析持仓，清仓取自轮动数据Rotated into轮入 (14)
| RLAY add |
10.9% | — |
| TXG add |
3.7% | — |
| SRRK add |
1.3% | +3% |
| AGMB new |
1.2% | — |
| HIMS add |
1.1% | +33% |
| TSHA add |
1.1% | — |
| GRAL new |
0.9% | — |
| PSNL new |
0.8% | — |
| MLTX new |
0.6% | — |
| NTLA new |
0.3% | — |
| IRON new |
0.3% | — |
| MRNA new |
0.3% | +37% |
| ANL new |
0.3% | — |
| GLUE add |
0.2% | — |
Rotated out of轮出 (8)
| ILMN trim |
-12% | +32% |
| BEAM trim |
-16% | — |
| GH trim |
-17% | +62% |
| PACB trim |
-83% | — |
 CI exit |
-100% | -1% |
 DXCM exit |
-100% | +25% |
 INCY exit |
-100% | +19% |
 UNH exit |
-100% | +7% |
Trade log交易记录
last 40 graded trades, filing-date anchored, newest first — variable hold vs SPY最近40笔已评分交易，以申报日为锚，最新在前——持有期不定，相对SPYNo graded trades available for this fund.该基金暂无已评分交易。
Caveats注意事项 —
13F = quarterly, ~45-day lag, long-only US listed ≥$100M. No shorts, no cash, no non-US positions. This desk is context — ownership is never a directional signal here.13F = 季度披露，约45天滞后，仅含美股多头且持仓≥1亿美元。不含空头、现金或非美股仓位。本台仅为背景参考——持仓数据在此永远不是方向性信号。
Grades and reliability are descriptive ranks within a curated survivor cohort — they measure what filings did after their filing dates, not a manager-selection edge. Conviction and core-lean reads are descriptive composites earning a forward record via the pre-registered ledger (L5); sector/theme classification applies the current map to history.评级与可靠性为精选幸存者队列中的描述性排名——衡量申报日之后持仓的表现，而非经理选择能力。信念分与核心倾向为描述性综合指标，通过预注册账本（L5）积累前瞻记录；行业/主题分类将当前映射应用于历史。